Analysis: Part D is main cause of $500B Medicare slowdown

Laura Pedulli | | Health Exec | Policy & Regulations

Prescription drug spending (or Part D) has accounted for more than 60 percent of the slowdown in Medicare benefits since 2011, according to an analysis presented in Health Affairs.

Unfortunately, “the outsized role that Part D has played in the Medicare slowdown is bad budget news because it may prove fleeting,” according to authors Loren Adler, research director for the Committee for a Responsible Federal Budget (CRFB) and Adam Rosenberg, policy analyst at CRFB.

Read more below:

The $500 Billion Medicare Slowdown: A Story About Part D

Laura Pedulli

Related Content

Bill to regulate healthcare private equity lands on desk of Mass. governor
The biggest obstacles facing radiology business managers in 2025
5 healthcare AI predictions for 2025 from Wolters Kluwer Health
Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Policies and regulations shaping radiology in 2025

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.